云南高校图书馆联盟文献共享服务平台- CANCERS

CANCERS: 作品数：353被引量：2621H指数：17; 导出分析报告; 相关领域：医药卫生生物学更多>>; 相关作者：夏厚军陈策实徐留柱刘端祺介雅慧更多>>; 相关机构：中南大学南京医科大学教育部中国科学院更多>>; 相关期刊：更多>>; 相关基金：国家自然科学基金国家重点基础研究发展计划中国博士后科学基金福建省自然科学基金更多>>

Emerging roles of small extracellular vesicles in metabolic reprogramming and drug resistance in cancers: 《Cancer Drug Resistance》2024年第1期332-356,共25页Jingcun Shi Ying Shen Jianjun Zhang; supported by grants from the Project of the National Natural Science Foundation of China(grant No.82372871 and 82173148 to Zhang J).; Studies of carcinogenic metabolism have shown that cancer cells have significant metabolic adaptability and that their metabolic dynamics undergo extensive reprogramming,which is a fundamental feature of cancer.The Wa...; 关键词：Small extracellular vesicles metabolic reprogramming drug resistance neoplasms GLYCOLYSIS lipid metabolism amino acid metabolism

Targeting T regulatory(T_(reg))cells in immunotherapy-resistant cancers: 《Cancer Drug Resistance》2024年第1期1053-1077,共25页Pavlina Spiliopoulou Paramjit Kaur Tracey Hammett Giusy Di Conza Michael Lahn; Primary or secondary(i.e.,acquired)resistance is a common occurrence in cancer patients and is often associated with high numbers of T regulatory(T_(reg))cells(CD4^(+)CD25^(+)FOXP3^(+)).The approval of ipilimumab and ...; 关键词：Primary and secondary resistance T regulatory cells flow cytometry mass cytometry hyperprogression

Reprogrammed lipid metabolism in advanced resistant cancers:an upcoming therapeutic opportunity: 《Cancer Drug Resistance》2024年第1期189-211,共23页Mario Cioce Mariamena Arbitrio Nicoletta Polera Emanuela Altomare Antonia Rizzuto Carmela De Marco Vito Michele Fazio Giuseppe Viglietto Maria Lucibello; Resistance of cancer to therapy is the main challenge to its therapeutic management and is still an unsolved problem.Rearranged lipid metabolism is a strategy adopted by cancer cells to counteract adversity during the...; 关键词：Metabolic signaling therapy resistance tumor microenvironment METASTASIS immune evasion

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers: 《Cancer Drug Resistance》2023年第1期35-44,共10页Rachel Bayley Ellie Sweatman Martin R.Higgs; supported by a PhD studentship from the University of Birmingham and Cancer Research UK(C17422/A25154)awarded to Sweatman E and Higgs MR;a Breast Cancer Now project grant(2019AugPR1320)supporting Bayley R(awarded to Garcia P);an MRC Career Development Fellowship(MR/P009085/1)awarded to Higgs MR.; The clinical treatment of DNA-repair defective tumours has been revolutionised by the use of poly(ADP)ribose polymerase(PARP)inhibitors.However,the efficacy of these compounds is hampered by resistance,which is attrib...; 关键词：Double strand break repair histone methylation PARP inhibitor RESISTANCE SETD1A BOD1L H3K4

Notch signaling in female cancers: a multifaceted node to overcome drug resistance: 《Cancer Drug Resistance》2021年第4期805-836,共32页Maria V.Giuli Angelica Mancusi Eugenia Giuliani Isabella Screpanti Saula Checquolo; Maria V.Giuli was supported by a AIRC fellowship for Italy.; Drug resistance is one of the main challenges in cancer therapy,including in the treatment of female-specific malignancies,which account for more than 60%of cancer cases among women.Therefore,elucidating the underlyin...; 关键词：Notch signaling drug resistance female-specific cancers cancer stem cells epithelial-to-mesenchymal transition drug efflux tumor microenvironment

PHGDH as a mechanism for resistance in metabolically-driven cancers: 《Cancer Drug Resistance》2020年第4期762-774,共13页Richa Rathore Charles R.Schutt Brian A.Van Tine; The authors would like to thank Dawn Merkel’s Bad to the Bone Chili Cook Off,Kellsie’s Hope Foundation;the National Institute of Health(NIH)-National Cancer Institute(NCI)(R01-CA227115)for funding.; At the forefront of cancer research is the rapidly evolving understanding of metabolic reprogramming within cancer cells.The expeditious adaptation to metabolic inhibition allows cells to evolve and acquire resistance...; 关键词：PHGDH CANCER METABOLISM SERINE one-carbon metabolism folate cycle drug resistance

Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications被引量：1: 《Cancer Drug Resistance》2020年第4期791-803,共13页Bao-Jie Zhang Deng Chen Frank J.Dekker Wim J.Quax; This research was partly funded by The Dutch Technology Foundation(STW)(No.11056);European Fund for Regional Development(KOP/EFRO)(No.068 and No.073).; Epigenetic regulation refers to alterations to the chromatin template that collectively establish differential patterns of gene transcription.Post-translational modifications of the histones play a key role in epigene...; 关键词：EPIGENETICS histone modification tumor necrosis factor-related apoptosis-inducing ligand selective epigenetic inhibitors APOPTOSIS

Application of liquid biopsy for prognostic status of cancers and drug response: 《Cancer Drug Resistance》2020年第4期1001-1002,共2页Dario Marchetti; The vast majority of cancer deaths(>94%)are due to the development of metastatic disease with a considerable fraction of patients experiencing metastatic relapse within five years from primary tumor resection,despite ...; 关键词：METASTASIS cancer GENERATING

Innate and adaptive resistance mechanisms to arginine deprivation therapies in sarcoma and other cancers: 《Cancer Drug Resistance》2019年第3期516-526,共11页Leonard C.Rogers Brian A.Van Tine; BAVT-reports a one year grant from Polaris,Inc.in 2014,unrelated;Basic Science Grant Funding from Pfizer,Tracon,and Merck;consulting fees from Epizyme,Lilly,CytRX,Janssen,Immune Design,Daiichi Sankyo,Bayer,Plexxicon and Adaptimmune;speaking fees from Caris,Janseen and Lilly;Travel support from Lilly;and is the overall principle investigator on(NCT03449901).; Many cancers lack functional expression of the enzyme argininosuccinate synthetase 1(ASS1)that is necessary for synthesis of L-arginine.These cancers must import arginine for survival and growth,and this reliance can ...; 关键词：PEGylated arginine deiminase argininosuccinate synthetase 1 resistance metabolism ARGININE

Molecular mechanisms of enzalutamide resistance in prostate cancer: 《Cancer Drug Resistance》2019年第2期189-197,共9页Eliot B.Blatt Ganesh V.Raj; This work was supported by the Department of Defense(W81XWH017-1-0674);the Prostate Cancer Foundation(18CHAL16);as well as support from the Cole Foundation and the Wilson Foundation.; An estimated 30,000 men in the United States will die of metastatic prostate cancer(PCa)each year due to the development of therapy resistance,most notably resistance to second-generation antiandrogen enzalutamide.The...; 关键词：Drug resistant cancers resistance modulation biomarkers of drug responsiveness targeted therapy resistance

CANCERS